Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

作者： Qiang Li*1, Xiaolan Wang*1,2, Deju Li*1, Yulong Liu*3, Kangshou Liu1, Junjie Liang1, Jian Sun1, Quan Jiang1, Jiexing Li1, Zhilong Liu1, Jian Gong4, Leyang Xiang1, Zhidong Jia1, Zhiwei Chen1, Mingrong Cao1, Yuchuan Jiang1,5 1Department of Hepatobiliary Surgery, The First Affiliated Hospital,Jinan University, 2Dongpu Branch,The First Affiliated Hospital, Jinan University, 3Department of Vascular Intervention, The First Affiliated Hospital,Jinan University, 4Department of Nuclear Medicine, The First Affiliated Hospital,Jinan University, 5Department of Gastroenterology,The Second Affiliated Hospital of Nanchang University

简介：

Overview

This study illustrates the potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as a neoadjuvant strategy for hepatocellular carcinoma (HCC) patients. It emphasizes the safety, feasibility, and procedural guidance of this approach.

Key Study Components

Area of Science

• Oncology
• Interventional Radiology
• Hepatology

Background

• Hepatocellular carcinoma (HCC) has a high recurrence risk post-surgery.
• Combining Y-90 TARE with PD-1 inhibitors may improve treatment outcomes.
• Understanding the tumor response is crucial for individual case treatments.
• Future research will explore molecular mechanisms and predictive biomarkers.

Purpose of Study

• To investigate the efficacy of Y-90 TARE combined with PD-1 inhibitors as a neoadjuvant therapy.
• To document tumor response in HCC patients with high recurrence risk.
• To provide a detailed procedural guide for this combined treatment approach.

Methods Used

• Patient preparation and procedural setup using the Seldinger technique.
• Super selective catheterization and angiography for targeted tumor treatment.
• Administration of Y-90 microspheres and imaging techniques for assessment.
• Histopathological evaluation post-surgery to assess treatment efficacy.

Main Results

• Significant tumor reduction observed post Y-90 TARE treatment.
• Initial alpha-fetoprotein levels decreased significantly after treatment.
• Safety and feasibility of the combined treatment were confirmed.
• Procedural guidance provided for future applications in clinical settings.

Conclusions

• The combination of Y-90 TARE and PD-1 inhibitors is a promising neoadjuvant strategy for HCC.
• Further studies are needed to explore molecular mechanisms and efficacy biomarkers.
• This approach may improve surgical outcomes and reduce recurrence rates in HCC patients.

Frequently Asked Questions